|Bid||0.00 x 3000|
|Ask||0.00 x 3200|
|Day's range||13.81 - 13.94|
|52-week range||13.81 - 19.97|
|Beta (5Y monthly)||1.10|
|PE ratio (TTM)||11.49|
|Forward dividend & yield||0.84 (6.04%)|
|Ex-dividend date||30 Mar 2021|
|1y target est||20.37|
Novavax CEO Stanley Erck discusses the company's first COVID-19 vaccine authorization filing, in the U.K., and how quickly other global filings are planned.
OSAKA, Japan, & LONDON, October 27, 2021--Takeda exercised its option to acquire GammaDelta Therapeutics, expanding Takeda's immuno-oncology and innate immune cell therapy portfolio.
Seagen (SGEN) focuses on improving sales of its marketed drugs that are approved for different types of cancer indications. Stiff competition in the target market remains a woe.